Company intelligence / Profile preview

AdJane

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

AdJane is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies and vaccines. The company utilizes its proprietary Ad-Jane adjuvant platform to discover and develop small molecule immune modulators, including STING agonists and TLR ligands. Its lead candidate, AJ002, is currently being evaluated in clinical trials for the treatment of advanced solid tumors. AdJane's approach emphasizes the activation of innate immunity to overcome the immunosuppressive tumor microenvironment. Based in Suzhou, China, the company is supported by prominent venture capital investors and aims to provide novel therapeutic options for oncology patients globally.

Therapeutic areas: Oncology
Modalities: Small moleculeVaccineAdjuvant
Industry: Biotech

Beyond the preview

Go deeper on AdJane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdJane.

Explore the full profile